Viscoelastic coagulation monitoring for tranexamic acid: personalised antifibrinolytic dosing?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38123441.
- Also identified by DOI 10.1016/j.bja.2023.11.041.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ex vivo viscoelastic testing can be used to assess the concentration responses to tranexamic acid in blood samples obtained from pregnant women across the three trimesters and in non-pregnant controls. Minor variations in fibrinolysis across pregnancy suggest a target tranexamic acid blood concentration of 12.5 mg L<sup>-1</sup> for complete inhibition of fibrinolysis. Although the data support the potential utility of viscoelastic testing using the ClotPro® TPA test in maintaining therapeutic tranexamic acid concentrations during postpartum haemorrhage, it might obscure potentially crucial endogenous fibrinolysis inhibitor interactions essential to the microcirculation.
Medical subject headings
- Antifibrinolytic Agents
- Blood Coagulation
- Tranexamic Acid